Vol 17 - Numéro 2 Supplément 1 - octobre 2025
P. 2S1-2S358© SPLF
Cours du Groupe d'Oncologie thoracique de Langue Française - GOLF 2025
Page :i
Page :ii
Page :iii
Page :v
Page :ix
Editorial: The 2025 GOLF Conference
Page :2S1
M. Duruisseaux, S. Couraud, A.-C. Toffart, A. Swalduz
Smoking cessation in daily practice
Page :2S3
A.-M. Ruppert, D. Glesener
Epidemiology and environmental and occupational risk factors of lung cancer
Page :2S8
J.-C. Pairon, L. Boudet, F. Delva, P. Andujar
Pulmonary oncogenesis: molecular foundations and therapeutic implications
Page :2S15
C. Ricordel, C. Pierre, Y. Le Guen, H. Lena
Genetic predisposition to lung cancer
Page :2S25
P. Benusiglio
Tissue biomarkers in NSCLC
Page :2S30
A. Mansuet-Lupo, K. Leroy, M. Wislez
Lung cancer: which molecular biology work up?
Page :2S38
C. Leonce, F. Escande, K. Leroy, C. Mascaux, C. Descarpentries, O. Farchi, H. Blons, M. Beau-Faller
The 9th TNM classification of thoracic oncology
Page :2S46
A. Agrafiotis, B. Grigoriu, P. Van Schil
Assessment of lung cancer: which radiological evaluation?
Page :2S60
G. Ferretti, L. Ruez-Lantuejoul, E. Reymond, A.-C. Toffart, A. Khalil, V. Gounant, S. Boussouar
Lung cancer screening
Page :2S68
S. Couraud, E. Grolleau, B. Milleron, V. Gounant, O. Leleu
When and how to perform lymph node staging?
Page :2S75
D. Basille
Surgery in early-stage lung cancer in 2024
Page :2S84
G. Drevet, E. Gagnepain, J.-M. Maury
Focus on stereotactic radiotherapy for the management of localized non-small cell lung cancer
Page :2S92
E. Martin, F. Bonnet, M. Rakotosamimanana, C. Chevalier, J. Baude
Perioperative treatments for non-small cell lung cancer (NSCLC): current standards and perspectives
Page :2S98
J. Slomka, G. Eberst, V. Westeel, M. Wislez
Radiotherapy for locally advanced non-small cell lung cancers
Page :2S106
I. Martel-Lafay
Role of immunotherapy in unresectable stage III NSCLC
Page :2S113
E. Giroux Leprieur, M. Pérol, J. Khalifa
Place of surgery in the treatment of locally advanced NSCLC
Page :2S121
G. Galvaing
Non-small-cell oligo-metastatic bronchial cancers, oligo-persistence, oligo-progression, residual disease: what are we talking about? What management?
Page :2S127
L. Bigay-Game, L. Alvarez, A. Rabeau, V. Gounant, C. Daigmorte, C. Mehlman, C. Joseph, Y.M. Xu, J.E. Simon, G. Zalcman
How to irradiate a patient under systemic treatment (targeted therapy, immunotherapy, ADC)?
Page :2S143
C. Le Péchoux, A. Mavrikios, A. Botticella, D. Lavigne, A. Camps-Malea, P. Abdayem, P. Lavaud, M. Frelaut, C. Parisi, J. Remon-Masip, A. Levy
Therapeutic algorithm for NSCLC without molecular anomaly actuatable in first-line treatment
Page :2S151
A.-C. Toffart, J. Mazières, M. Pérol, E. Berton, A. Cortot, D. Moro-Sibilot
Treatment algorithm after frontline treatment in NSCLC without oncogenic addiction
Page :2S160
M. Pérol, D. Moro-Sibilot
Antibody drug conjugates in non-small cell lung cancer: where do we stand?
Page :2S171
D. Bruyat, P. Tomasini
Innovative therapeutic antibodies in non-small cell lung cancer: beyond conventional targets
Page :2S180
E. Pons-Tostivint, J. Bennouna
Therapeutic algorithm of EGFR mutation driven non-small cell carcinoma
Page :2S192
M. Ferreira, V. Fallet, S. Baldacci, A.B. Cortot, J. Cadranel
Therapeutic algorithm for non-small cell lung cancers with ALK, ROS1 and RET fusions
Page :2S213
A. Swalduz, A. Cortot, M. Duruisseaux
Non-Small Cell Lung Cancers with KRAS mutations
Page :2S221
A. Chour, C. Lafitte, M. Boussageon, T. Pierret, M. Duruisseaux
Non-small cell lung cancer with other targetable mutations ( BRAF, MET, HER2 )
Page :2S230
A. Mogenet, A. Cortot, P. Abdayem, D. Planchard, L. Greillier
Classification of pulmonary neuroendocrine neoplasms and impacts on clinical practice
Page :2S237
S. Lantuejoul, F. Forest, F. Damiola, D. Moro-Sibilot, L. Falchero
Management of limited-stage small cell lung cancer: an update
Page :2S245
S. Thureau, E. Nicolas, C. Faivre-Finn, E. Giroux Leprieur, S. Ocak, P. Fournel, E. Negre, B. Roch, C. Le Péchoux
Exensive-stage small cell lung cancer: what’s new?
Page :2S253
D. Moro-Sibilot, S. Ocak, C. Ardin, E. Berton, P. Fournel, A.-C. Toffart
Pulmonary neuroendocrine neoplasias excluding small cell lung cancers: carcinoid tumors and large-cell neuroendocrine carcinomas
Page :2S261
L. Odier, M. Darrason, M. Duruisseaux, T. Walter, L. Gérinière, A. Durand, D. Arpin
Pleural mesothelioma: therapeutic algorithm
Page :2S270
M. Locatelli-Sanchez, A. Scherpereel, N. Venissac, S. Humez, L. Ulmer, S. Brosseau, X. Dhalluin, D. Nunes, V. Gounant, S. Lantuejoul, G. Zalcman
Thymic tumors: surgical management
Page :2S279
G. Drevet, E. Gagnepain, L. Chalabreyse, C. Lafite, T. Pierret, J.-M. Maury
Thymic tumors: systemic treatments and role of radiotherapy
Page :2S286
T. Pierret, M. Duruisseaux, C. Lafitte, M. Boussageon, L. Chalabreysse, J.-M. Maury, M. Le Bon, B. Besse, N. Girard
Brain metastases and carcinomatous meningitis of bronchial cancers
Page :2S294
C. Decroisette, E. Perrot, P. Tomasini
Admission to critical care units and level of life-sustaining therapies: application to lung cancer?
Page :2S305
G. Dumas, C. Ardin, G. Berardi, F. Gonzalez, A.-C. Toffart
Interventional bronchoscopy (debulking and prothesis)
Page :2S311
C. Lorut, A. Lefebvre, H. Joumaa, J. Marey, F. Giraud, L. Regard
Systemic management of lung cancer in elderly
Page :2S318
L. Pabst, R. Corre, E. Quoix, C. Mascaux
Special Populations: Patients with Performance Status 2 or higher
Page :2S329
V. Gounant, L. Alvarez, Y.M. Xu, C. Mehlman, L. Nicolas, S. Guillerm, P. Mordant, G. Zalcman
Thromboembolic diseases and lung cancer
Page :2S341
G. Poenou, C. Marie-Sainte, A.-L. Desage, C. Gravelier, S. Accassat, L. Bertoletti
Lung cancers associated with fibrosing interstitial lung disease
Page :2S350
B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, K. Chouahnia, J. Behr, P.-Y. Brillet, H. Nunes
EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.
En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.
Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.